Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Slit2N is the N-terminal fragment (120-140 kDa) of the secreted glycoprotein Slit2, which serves as a ligand for Roundabout (Robo) receptors, particularly Robo1. It inhibits HIV-1 transmission from dendritic cells to T-cells by blocking HIV-1-induced cytoskeletal rearrangements, including filopodial extensions, through suppression of signaling pathways involving Cdc42, Src, Arp2/3, Diaph2, WASp, and interactions with Flightless-1 (Fli1). Slit2N has been studied in recombinant form for potential therapeutic applications in viral infections, vascular stabilization, inflammation, and neuroprotection, with research exploring its roles in HIV inhibition, hemorrhagic fever, and nerve repair.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Slit2N.